Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVETUXIRI: Avelumab + Cetuximab + Irinotecan in MSS mCRC
NCT03608046Phase 2Unknown
- Start
- Oct 2018
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in metastatic colorectal cancer (mCRC). Status: unknown.
02
Drugs
avelumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03608046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608046.